Clinical trials: sponsored by Xijing Hospital
Breast Cancer Stage II
Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer
Anlotinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. Combining anti-angiogenesis with chemotherapy yielded increased response rates in patients with early-stage…
- Trial name
- ACNTBC (NCT05558722)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Gout
Safety and Efficacy of Oral Febuxostat in Subjects With Gout
The purpose of this study is to compare febuxostat allopurinol in subjects with gout.
- Trial name
- NCT02082769
- Testing
- Febuxostat, Allopurinol
- Volunteers
- 504 people
- Sponsor
- Xijing Hospital